

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Svane 1



Section 1. Identifying Inform	mation	
1. Given Name (First Name) Maria	2. Surname (Last Name) Svane	3. Date 16-June-2016
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title Medicin vs kirurgi til bahandling af ove	ervægtige med type 2 diabetes	
6. Manuscript Identifying Number (if you k UFL-06-16-0418	know it)	
Section 2. The Work Under (Consideration for Publication	
	eive payment or services from a third party (government, or government) and be used to grants, data monitoring board, study rest?	
Section 3. Relevant financia	activities outside the submitted work.	
of compensation) with entities as desc clicking the "Add +" box. You should re Are there any relevant conflicts of inte	in the table to indicate whether you have financial ribed in the instructions. Use one line for each entity eport relationships that were present during the 36 rest? Yes V No	; add as many lines as you need by
Section 4. Intellectual Prope	erty Patents & Copyrights	
Do you have any patents, whether plan	nned, pending or issued, broadly relevant to the wor	k? ☐ Yes 🗸 No

Svane 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Svane has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Svane 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Bojsen-Møller 1



Cartinus				
Section 1. Identifying Inforn	nation			
1. Given Name (First Name) Kirstine Nyvold	2. Surname (Last Name) Bojsen-Møller		3. Date 16-June-2016	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho Maria Saur Svane	r's Name	
5. Manuscript Title Medicin vs kirurgi til behandling af ove	rvægtige med type 2 diab	etes		
6. Manuscript Identifying Number (if you ki UFL-06-16-0418	now it)	_		
Section 2. The Work Under C	onsideration for Public	cation		
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to grants, da			
Section 3. Polyant financial	activities outside the			
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of interesting the second conflicts of the sec	in the table to indicate while in the instructions. Use port relationships that we lest? Yes Moormation below.	ether you have financ se one line for each en re present during the	tity; add as many lines as you	need by
Name of Entity	Grant? Personal Noi	n-Financial other?	Comments	
Danish Council for Independent Research	✓			
Novo Nordisk Foundation (co-applicant)	✓			
Eli Lilly (Speaker fee)				
Danish Diabetes Academy (speaker fee)				

Bojsen-Møller 2



Section 4. Intellectual I	Property Patents & Copyrights
Do you have any patents, wheth	er planned, pending or issued, broadly relevant to the work? Yes 🗸 No
Section 5. Relationship	os not covered above
	activities that readers could perceive to have influenced, or that give the appearance of
Yes, the following relationsh	ips/conditions/circumstances are present (explain below):
✓ No other relationships/condi	tions/circumstances that present a potential conflict of interest
	tance, journals will ask authors to confirm and, if necessary, update their disclosure statements athors to disclose further information about reported relationships.
Section 6. Disclosure S	tatement
Based on the above disclosures, below.	this form will automatically generate a disclosure statement, which will appear in the box
	s from Danish Council for Independent Research, grants from Novo Nordisk Foundation (coli Lilly (Speaker fee), personal fees from Danish Diabetes Academy (speaker fee), outside the

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Bojsen-Møller 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Madsbad 1



Section 1. Iden	tifying Informatio	on		
Given Name (First Nam Sten		Surname (Last Name) adsbad		3. Date 16-June-2016
4. Are you the correspond	ling author?	Yes ✓ No	Corresponding Autho	or's Name
5. Manuscript Title Medicin vs kirurgi til be	handling af overvæg	tige med type 2 dial	petes	
6. Manuscript Identifying UFL- 06-16-0418	Number (if you know it	:)		
Section 2. The N	Work Under Consi	deration for Publ	ication	
	ed work (including but i			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Section 3. Relev	ant financial activ	vities outside the	submitted work.	
of compensation) with clicking the "Add +" box	entities as described k. You should report i	in the instructions. Urelations with the instructions in the transfer of the t	Jse one line for each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication .
Are there any relevant of the lif yes, please fill out the		✓ Yes No		
Name of Entity	Gr	ant? Personal No	on-Financial Other?	Comments
Novo Nordisk		√		
Region hovedstaden		✓		
Section 4. Intel	lectual Property	· Patents & Copyr	ights	
Do you have any patent	ts, whether planned,	pending or issued, k	proadly relevant to the	work? Yes V No

Madsbad 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
✓ Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
served as a consu	
Zeneca, Johnson	ceuticals, Novo Nordisk, Merck Sharp & Dohme, Pfizer A/S, Abbott Laboratories, Sanofi Aventis, Astra & Johnson, Roche, Mankind, BMS, Intarcia, Boehringer-Ingelheim, Eli Lilly, Amgen
	speaking: erck Sharp & Dohme, Astra Zeneca, Johnson & Johnson, Abbott Laboratories, Pfizer A/S, Roche, Schering- ventis, Eli Lilly, Novartis Pharmaceuticals, BMS, Boehringer-Ingelheim, Takeda

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Madsbad reports grants from Novo Nordisk, grants from Region hovedstaden, outside the submitted work; and served as a consultant or adviser:

Novartis Pharmaceuticals, Novo Nordisk, Merck Sharp & Dohme, Pfizer A/S, Abbott Laboratories, Sanofi Aventis, Astra Zeneca, Johnson & Johnson, Roche, Mankind, BMS, Intarcia, Boehringer-Ingelheim, Eli Lilly, Amgen Received fee for speaking:

Novo Nordisk, Merck Sharp & Dohme, Astra Zeneca, Johnson & Johnson, Abbott Laboratories, Pfizer A/S, Roche, Schering-Plough, Sanofi-Aventis, Eli Lilly, Novartis Pharmaceuticals, BMS, Boehringer-Ingelheim, Takeda.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Madsbad 3